AP-161™

About Alphageneron Pharmaceuticals

Alphageneron Pharmaceuticals is a clinical-stage biotech pioneering a targeted NK cell therapy platform centered on the cancer-specific biomarker mHsp70. Its pipeline includes both autologous and allogeneic NK cell therapies, as well as a CAR-NK candidate derived from induced pluripotent stem cells (iPSCs). Led by a founder with a history of biotech ventures and a board featuring seasoned industry and academic experts, the company is positioned in the competitive but high-potential cell therapy space for solid tumors.

Therapeutic Areas

Other mHsp70+ Cancers Drugs